1. Introduction {#sec1}
===============

Sepsis is a life-threatening organ dysfunction caused by a dysregulation of host responses to infection \[[@B1]\]. Despite significant medical progress, it remains an often fatal condition with mortality reaching 25% \[[@B2]\]. Sepsis accounts for a large number of Emergency Department (ED) visits in the United States \[[@B3]\], and leads to more than half of in-hospital mortality \[[@B4]\]. A delay in initiating antibiotic therapy and fluid therapy is detrimental in sepsis management \[[@B5], [@B6]\].

In 2001, the early goal directed trial EGDT \[[@B7]\] introduced a 6-hour-protocol approach that resulted in a dramatic reduction in mortality from sepsis. This lead to the establishment of the Surviving Sepsis Campaign regularly updating sepsis management guidelines \[[@B1]\]. Recently three trials, ARISE, PROMISE, and Process, challenged the EGDT and showed similar survival with standard care \[[@B8]--[@B10]\], and this result was replicated by PRISM, a meta-analysis published in 2016 \[[@B11]\]. These trials were conducted in developed countries \[[@B11], [@B12]\] with rare studies exploring sepsis management in developing countries where hospital and human resources are limited \[[@B13]\]. Studies from Africa and the Middle East suggest a decreased mortality with the use of EGDT \[[@B14]\].

The primary outcome of our study is the 72 hours, hospital, and 28-day mortality to evaluate the implications of a structured sepsis protocol derived from the 2001 EGDT in patients presenting to the emergency department of a single tertiary hospital in Lebanon.

Secondary outcomes includes length of stay, time to antibiotics, percent of ICU admission, amount of IV fluid use, and vasopressor use.

2. Methods {#sec2}
==========

2.1. Study Design and Patient Selection {#sec2.1}
---------------------------------------

This is an IRB approved, single center, retrospective, cohort study conducted in a large tertiary care center in Lebanon. We reviewed the electronic health record using the ICD-9 coding system of patients presenting to the emergency department with severe sepsis or septic shock. Patients who were eligible for the study should meet the definition of severe sepsis or septic shock as per the 2012 Surviving Sepsis Campaign guidelines definitions \[[@B15]\]. Severe sepsis was defined as sepsis with associated organ dysfunction with one of the following: SBP \<90mmHg or MAP \<65mmHg or lactate \>2mmol/L after an initial fluid challenge; INR \>1.5 or a PTT \>60s; bilirubin \>2 *μ*mol/L; urine output \<0.5ml/kg/hr for 2hrs; creatinine\>2mg/dl; platelet count \<100,000/mm^3^; SpO~2~ \<90%. Septic shock was defined as sepsis with any of the following: SBP \<90mmHg or MAP \<65mmHg despite 30ml/kg of crystalloid resuscitation (i.e., vasopressor dependence). We excluded patients younger than 18 years of age, pregnant, or presenting with cardiac arrest or trauma.

We included 145 consecutive patients from January 2013 until May 2014 presenting to our ED with severe sepsis and/or septic shock who were managed by the EGDT sepsis based protocol, and these constituted the intervention arm. For the control cohort, 145 patients with sepsis and/or septic shock presenting to the ED between January 2010 and December 2012 were randomly selected from a large pool of database using computer software for random number generation. The AUBMC-ED volume of patients diagnosed with severe sepsis and started on the protocol during the years following implementation of a sepsis protocol (2012-2014) was used to determine the size of the study population. A rough estimate of each group size ranges between 200 and 300 patients.

Medical records were used to retrieve data about patients\' demographics including patients\' age, gender and medical information regarding presence/absence of comorbidities, site of infection, microbiology findings, and site of disposition (intensive care unit ICU, general practice unit GPU or home). Pertinent laboratory blood workup and vital signs upon presentation and the latter 6 hours after resuscitation were also collected. Antibiotics use and its appropriateness (defined as initial antibiotic regimen used in the first 48hrs of treatment that matches the bacteria later recovered) were extracted. Data on the requirements of intravenous fluid resuscitation, vasopressor (use and duration) and steroid use were also retrieved. We also collected the length of stay in the ED, GPU and ICU along with in-hospital and 72-hr mortality.

2.2. EGDT-Sepsis Based Protocol Definition {#sec2.2}
------------------------------------------

For the intervention cohort, patients were managed as per our ED sepsis protocol (Supplementary Materials [available here](#supplementary-material-1){ref-type="supplementary-material"}), that is, based on the EGDT recommendations \[[@B7]\].

2.3. Usual Care Definition {#sec2.3}
--------------------------

For the control cohort, the management was not standardized and was left as per the treating the physician, guided by individual preference practice.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analyses were performed using SPSS version 24.0 (Armonk, NY: IBM Corp).

Univariate analysis was carried out between the intervention and the control groups for comparison of patients\' characteristics, preresuscitation parameters, resuscitation parameters, and length of hospital stay/mortality outcomes. Comparison was done between patients\' demographics, comorbidities, severity of sepsis, site of infection, and microbiology isolate ([Table 1](#tab1){ref-type="table"}). Preresuscitation parameters included vital signs and pertinent laboratory findings upon presentation ([Table 2](#tab2){ref-type="table"}). As for the parameters of resuscitation, they included patients\' vital signs 6 hours after ED management, requirements of intravenous fluids at 6 and 24 hours, vasopressor/inotrope (use, time to start, and duration of use within the first 24 hours), CVC placement, and requirement of mechanical ventilation ([Table 3](#tab3){ref-type="table"}). As for length of hospital stay (in ED, ICU, and GPU and in-hospital), 72hours and 28 days mortality were compared between the two arms ([Table 4](#tab4){ref-type="table"}). For continuous variables, an independent t-test comparing the mean across both groups was done and both, the mean and standard deviation, are shown. For categorical variables, a chi-square test was run and data is represented as frequency percentages.

A multivariate analysis was performed using logistic regression to find the best model that fits the data and explains the use of the EGDT-sepsis based protocol as predictor of in-hospital mortality while controlling for all possible confounders. A backward selection procedure, with significance level for removal from the model set at 0.1, was conducted by fitting in-hospital mortality with all risk factors found to be significant in the bivariate level, in addition to those considered as being clinically meaningful. The included variables were protocol use, age, gender, diagnosis (severe sepsis or septic shock), systolic congestive heart failure (CHF) EF\<40%, diabetes mellitus (DM), coronary artery disease (CAD), hypertension (HTN), cerebrovascular accidents (CVA), chronic kidney disease (CKD), hemodialysis (HD), chronic obstructive pulmonary disease (COPD), central venous catheter (CVC) placement, endotracheal tube placement, MAP upon presentation to the ED, BUN, creatinine, and appropriate use of antibiotics.

3. Results {#sec3}
==========

3.1. Patients Characteristics {#sec3.1}
-----------------------------

Two hundred and ninety patients were included in the final analysis with 145 patients in each arm. The protocol arm had a mean age of 71.9 ± 14.1 years compared to 72.9 ± 16.3 years in the control arm. 51.7% and 52.4% of the protocol group and control group, respectively, were male patients. All baseline demographics such as age, gender, and studied comorbidities in addition to diagnosis of severe sepsis or septic shock are presented ([Table 1](#tab1){ref-type="table"}). The most common sites of infection in the protocol arm were respiratory (42.1%), urinary (35.9%) and gastrointestinal (14.5%) tracts compared to the control arm that had urinary (33.8%), respiratory (31.0%) tracts, and skin (13.1%). Both cohorts did not differ significantly in regards to the microbiology results except for enterococcus being more prevalent in the control arm ([Table 1](#tab1){ref-type="table"}).

3.2. Pre-Resuscitation Parameters {#sec3.2}
---------------------------------

There was no statistically significant difference between the two groups in terms of temperature, O~2~ saturation, SBP, or respiratory rate. Protocol patients had higher diastolic blood pressure (DBP=59.2 ± 16.3 mmHg vs. 54.7 ±16.0 mmHg p=0.019) and mean arterial pressure (MAP= 73.7 ±17.3 mmHg vs. 69.5 ± 17.6 mmHg p=0.043) and heart rate (HR= 106.2 ±24.2 bpm vs. 99.4 ± 25.3 bpm). When comparing initial laboratory results, most results were comparable between the groups except for creatinine (2.0 ± 1.4 mg/dl vs. 2.8 ± 2.2 mg/dl in the protocol and control groups, respectively, p=\<0.001) and BUN (41.9 ± 29.9 mg/dl vs. 55.9 ± 39.5 mg/dl in the protocol and control groups, respectively, p=0.001). Lactate levels did not differ between the two groups (3.9 ± 2.5 mg/dl in the intervention cohort versus 3.8 ± 4.1 in the control cohort). [Table 2](#tab2){ref-type="table"} includes those parameters upon presentation to the ED.

3.3. Resuscitation Parameters {#sec3.3}
-----------------------------

All vital signs were comparable between the groups after treatment, except for MAP where protocol patients had a lower MAP than the control group at 6 hours (69.8 ± 13.8 mmHg vs. 73.9 ± 14.9 mmHg, respectively, p=0.022). Patients who were managed using the sepsis protocol received more fluids at 6 and 24 hours (3.8 ± 1.7 L and 6.1 ± 2.1 L) compared to the control group (2.7 ± 2.0 L and 4.9 ± 2.8 L) p=\<0.001. More vasopressors were initiated within the first 24 hours in the protocol arm as well (88 (60.6%) vs. 52 (35.8%) p=\<0.001). The intervention group had more CVC placed (21.2% vs. 9.9% p=0.010). Both protocol and control cohorts have similar rates of mechanical ventilation. The time to vasopressor initiation and the duration of vasopressor use were not significantly different between the cohorts. Both cohorts had similar steroid and antibiotic use. The mean time of antibiotics initiation was 2.0 ± 3.6 hours in the protocol group compared to 2.8 ± 2.6 hours in the control group p=0.054. More antibiotics were initiated in the ED in the control arm than the protocol arm (99.3% vs. 93.8% p=0.010). Ninety-one patients (97.8%) in the intervention group received appropriate antibiotics compared to 75 (91.5%) in the control group (p=0.056). [Table 3](#tab3){ref-type="table"} summarizes the vital signs 6 hours after treatment and the general parameters of the resuscitation.

3.4. Length of Stay and Mortality Analysis {#sec3.4}
------------------------------------------

The length of stay in the ED was found to be 26.0 ± 29.0 hours vs. 19.4 ± 28.8 hours in the protocol and control group, respectively (p=0.051). ICU and GPU LOS did not differ between the two arms ([Table 4](#tab4){ref-type="table"}). Forty-six (31.7%) protocol patients died during their hospital stay compared to sixty-nine (47.6%) control patients (p=0.006). When all statistically and clinically relevant variables were controlled for, protocol patients had an adjusted odds ratio of dying in hospital of 0.429 (Cl 95% 0.213-0.864 p =0.018) when compared to the control group ([Table 5](#tab5){ref-type="table"}). The relative risk reduction was found to be 33.3%.

4. Discussion {#sec4}
=============

This study attempts to evaluate the utility and efficacy of using EGDT-sepsis based protocol on sepsis management at a tertiary care centre in Beirut. The primary outcome is in-hospital mortality; the secondary outcomes were 28-day mortality, ED, and hospital length of stay. After the introduction of the EGDT in the USA, clinical outcomes of septic patients substantially improved \[[@B7]\] and mortality from sepsis decreased \[[@B16], [@B17]\]. Novel interventions ranged from prehospital recognition and management of sepsis \[[@B18]\] to in-hospital optimization of care \[[@B6], [@B19], [@B20]\]. In Lebanon, data from national registries on mortality secondary to sepsis are still lacking. And the guidelines from the Surviving Sepsis Campaign are not adopted nationally, where the standard of care remains ill-defined \[[@B21]\]. To our knowledge, our study is the first to assess the impact of implementing EGDT sepsis based protocol in the emergency department on mortality outcomes in Lebanon. Our results show lower in-hospital mortality from sepsis after the introduction of the protocol, 31.7% compared to 47.6% when on "usual care," before the protocol implementation. These findings are similar to the hospital mortality noted in the first EGDT paper (30.5% and 46.5% respectively) but higher than those reported in the more recent ProCESS, ARISE, and ProMISe trials \[[@B11]\]. Prehospital management of sepsis has a contributing impact on ultimate outcomes \[[@B22]\] and Lebanon lacks the infrastructure for prehospital sepsis management due to limited resources \[[@B23]\]. We assume that mortality is higher in our cohort compared to developed countries because prehospital care in Lebanon is not optimized \[[@B24]\].

4.1. Effectiveness of the Bundle {#sec4.1}
--------------------------------

Adherence to the sepsis protocol was associated with a relative risk reduction (RRR) on in-hospital mortality of 33.3%. This is in line with the findings of the Rivers \[[@B7]\] and others \[[@B25]\] where the RRR ranged from 24.3% to 45% \[[@B11]\]. Our protocol-based care was associated with an adjusted odds ratio (AOR) for hospital mortality of 0.429 (Cl 95% 0.213-0.864 p =0.018).

Several studies questioned the effectiveness of the EGDT protocol versus standard care and showed that alternate strategies may have equal effect at reducing mortality without the increased costs \[[@B8]--[@B10]\]. Those studies highlight the need for "unbundling" the sepsis protocol to better define which intervention is most important while gauging specific clinical endpoints. A "single intervention" analysis in our paper is not possible as controlling for other interventions is not feasible. we noticed a more conservative approach to CVC placement in our study in both arms, the intervention and the control, 21.2% and 9.9%, respectively, compared to that reported in the EGDT and other trial were more than 50% of the control population had a CVC inserted \[[@B8]\]. This lower rate is potentially explained by the stipulated endpoints in our protocol: MAP (via non-invasive blood pressure readings) and urine output. While CVP measurement via CVC insertion was kept an optional clinical decision, our physicians were most of the times not driven by the indication of getting a CVP measurement to insert a CVC. This approach was supported by a meta-analysis that included 24 studies looking at the role of CVP measurement on fluid responsiveness and found a poor association \[[@B26]\]. Despite the difference in invasive monitoring rates in our study and other trials, mortality was reduced and at a comparable RRR. This finding might support the "unbundling" approach to invasive monitoring in resources-limited settings where cost and resources may become restrictive.

4.2. ED Length of Stay {#sec4.2}
----------------------

Patient\'s length of stay in the ED and delayed transfers to the ICU have come under discussion in recent years \[[@B22], [@B26]\]. Some proposals have targeted ED times, such as the 4-hour rule \[[@B27]\], and other studies have shown an increased hospital stay and mortality with delayed patient transfer from the emergency department to the ICU \[[@B28], [@B29]\]. However, the length of stay in the ED in our study in both groups, the protocol and the control, was longer than that in the literature, 26.0 ± 29.0 hours and 19.4 ± 28.8 hours, respectively. This finding can be partially explained by the hospital\'s limited capacity of ICU beds \[[@B21]\]. In addition, the protocol arm had longer ED stay than the control arm, but it was not statistically significant. We explain this observed difference by the new introduction of the protocol in our ED, as the staff was in the training process to acquire the skills of the formulated protocol \[[@B30]\]. Moreover, the implementation of the new sepsis bundle was more time consuming, as it requires the use of more resources such as IV resuscitating fluids, vasopressors, monitoring, CVC placement and waiting for laboratory and radiology results. Delays in patient transfer from the ED to ICU in sepsis are well studied and correlate usually with worse outcomes. Despite the observed longer stay in the ED in our study, the mortality rate was still reduced at a comparable relative risk reduction to the EGDT trial.

4.3. Antibiotic Therapy {#sec4.3}
-----------------------

Our study showed that fewer patients were started on antibiotics in the ED in the protocol arm despite a lower mortality in this group. This finding relates to ongoing antimicrobial stewardship efforts \[[@B30]\]. It is crucial to promptly initiate antibiotic therapy in septic patients \[[@B31]\]; however, it is vital to apply standards of antimicrobial stewardship \[[@B32]\] as we are losing the battle against multidrug resistant organisms \[[@B33]\]. By following the protocol for sepsis management, we circumvented the initiation of unnecessary antibiotics. Though it did not reach significance, antibiotics were more used appropriately in the protocol arm than the control arm 91 (97.8%) vss. 75 (91.5%) (p=0.056). This reduction in inappropriate empiric antibiotic use might reflect positively on the cost, potential side effects, and complications. However, this study was not powered to test this hypothesis and we believe that future research in this direction would provide data to the gap in this knowledge.

5. Strengths and Limitations {#sec5}
============================

This is the first study to be conducted in Lebanon assessing the effect of implementing an EGDT sepsis based protocol in ED on mortality outcome. The retrospective design of the study is a main limitation of the study as data collected from the electronic health records may sometimes be misinterpreted or missing. To minimize the information bias, frequent meetings were held between the investigators to standardize the data collection process. In addition, we were not able to use a matched control group. We included all patients who presented with sepsis between January 2013 and May 2014 to ensure a large sample size.

The definition of "usual care" is not standard and was per the treating physician, thus comparing the management across the two arms is limited. The control group in our study did receive timely antibiotics, vasopressors, and IV fluids. Data about the paramedical care was not available; therefore we were not able to adjust for it in our analyses. The two cohorts were not matched, and the control arm subjects were sicker at baseline, showing worse hemodynamics upon presentation to the ED. These points might be explained by the inaccuracy of the non-invasive measurements. They had lower diastolic blood pressure (DBP=54.7 ±16.0 mmHg vs. 59.2 ± 16.3 mmHg p=0.019) and mean arterial pressure (MAP= 73.7 ±17.3 mmHg vs. 69.5 ± 17.6 mmHg p=0.043) when compared to the intervention arm. These findings might not be pertinent clinically as both groups had similar lactate and arterial pH. Those markers are indicators of end-organ hypoperfusion \[[@B34]\]. Moreover, despite less fluid and vasopressor use in the control arm, this group had higher MAP after 6 hours of resuscitations (73.9 ± 14.9 mmHg vs. 69.8 ± 13.8 mmHg, respectively, p=0.022). However, patients of the control cohort had more severe kidney injury at baseline compared to intervention cohort, with higher creatinine (2.8 ± 2.2 mg/dl vs. 2.0 ± 1.4 mg/dl, respectively, p=\<0.001) and BUN (55.9 ± 39.5 mg/dl vs. 41.9 ± 29.9 mg/dl, respectively, p=0.001). The internal validity of our study is limited by the missing data on the urine output, that was used as an endpoint in the sepsis protocol and the units of blood transfusions received in both groups. It is unclear which parts of the bundle contribute to the noted difference in mortality between the two groups. There is continued work in developed countries to decipher the most impactful parts of the EGDT protocol. In countries with limited resources, it is potentially more critical to determine those fundamental factors in order to decrease the effort and resources required to effectively treat sepsis. Finally, our study is not generalizable, as it is limited to one center in Lebanon and further multicenter studies are needed.

6. Conclusion {#sec6}
=============

In a single tertiary center in Lebanon, the introduction of an EGDT-based sepsis protocol decreased in-hospital mortality of patients presenting with severe sepsis or septic shock. 28-day sepsis mortality is also reduced after the implementation of the EGDT protocol. Although the utility of EGDT bundles has been under scrutiny in recent years, their benefits when used in countries with limited resources, ICU capabilities and pre-hospital systems may be pronounced. In conclusion, this study highlights several potentially important points. The introduction of a structured approach to sepsis is feasible in a resource limited setting; the results achieved in terms of reduced mortality are comparable to those demonstrated in developed countries. Outcomes could be further improved, especially regarding the baseline mortality by improving the existing pre-hospital infrastructure to ensure expedited and appropriate treatment of septic patients.

BP:

:   Blood pressure

BUN:

:   Blood urea nitrogen

CAD:

:   Coronary artery disease

CHF:

:   Congestive heart failure

COPD:

:   Chronic obstructive pulmonary disease

CVC:

:   Central venous catheter

CVP:

:   Central venous pressure

DBP:

:   Diastolic blood pressure

DM:

:   Diabetes mellitus

ED:

:   Emergency Department

EGDT:

:   Early Goal Directed Therapy

EHR:

:   Electronic health record

EM:

:   Emergency medicine

ET:

:   Endotracheal tube

GPU:

:   General practice unit

HR:

:   Heart rate

HTN:

:   Hypertension

ICU:

:   Intensive care unit

INR:

:   International normalised ratio

LOS:

:   length of stay

MAP:

:   Mean arterial pressure

RR:

:   Respiratory rate

RRR:

:   Relative risk reduction

SBP:

:   Systolic blood pressure

SSC:

:   Surviving Sepsis Campaign.

Data Availability
=================

The protocol dataset applied in the intervention arm, used to support the findings of this study, is included within the supplementary material.

Disclosure
==========

Nisrine Rizk is the corresponding and submitting author.

Conflicts of Interest
=====================

Authors declare no conflicts of interest.

Supplementary Materials {#supplementary-material-1}
=======================

###### 

Sepsis protocol order set that was used in the case arm.

###### 

Click here for additional data file.

###### 

Patient demographics.

  ---------------------------- --------------------- -------------------- -------------
                               **Protocol N= 145**   **Control N= 145**   **p-value**
                                                                          
  **Continuous mean ± SD**                                                 
                                                                          
  Age (years)                  71.9 ± 14.1           72.9 ± 16.3          0.573
                                                                          
  **Categorical no.(**%**)**                                               
                                                                          
  Male                         75 (51.7)             76 (52.4)            0.906
                                                                          
  Diagnosis                                                               0.280
   Septic shock                92 (63.4)             83 (57.2)            
   Severe sepsis               53 (36.6)             62 (42.8)            
                                                                          
  HTN                          102 (70.3)            101 (69.7)           0.898
                                                                          
  DM                           71(49.0)              68 (46.9)            0.724
                                                                          
  CAD                          64 (44.1)             59 (40.7)            0.552
                                                                          
  Systolic CHF: EF\<40%        32 (22.1)             29 (20.0)            0.666
                                                                          
  COPD/Emphysema               13 (9.0)              19 (13.1)            0.261
                                                                          
  CKD on HD                    4 (2.8)               5 (3.4)              0.735
                                                                          
  CVA                          19 (13.1)             20 (13.8)            0.863
                                                                          
  Site of Infection                                                       \<0.001^∗^
   Lung                        61 (42.1)             45 (31.0)            
   Gastrointestinal            21 (14.5)             11 (7.6)             
   Urine                       52 (35.9)             49 (33.8)            
   Skin                        6 (4.1)               19 (13.1)            
   Bile                        0 (0.0)               5 (3.4)              
   Liver                       0 (0.0)               1 (0.7)              
   Undetermined                5 (3.4)               15 (10.3)            
                                                                          
  Microbiology Isolate                                                     
                                                                          
   CoNS^1^                     1 (0.7)               2 (2.1)              0.562
                                                                          
   Staphylococcus aureus       6 (4.1)               3 (2.1)              0.310
                                                                          
   Escherichia coli            44 (37.9)             61 (42.1)            0.472
                                                                          
   klebsiella pneumonia        9 (6.2)               11 (7.6)             0.643
                                                                          
   pseudomonas aeroginosa      12 (8.3)              7 (4.8)              0.235
                                                                          
   Acinetobacter baumani       8 (5.5)               5 (3.4)              0.395
                                                                          
   Enterococcus spp.           2 (1.4)               9 (6.3)              0.030^∗^
                                                                          
   Proteus mirabillis          4 (2.8)               7 (4.8)              0.356
                                                                          
   Streptococcus spp.          9 (6.2)               6 (4.1)              0.426
                                                                          
   Clostridium spp.            3 (2.1)               1 (0.7)              0.314
                                                                          
   Others^2^                   3 (2.1)               0 (0.0)              0.281
  ---------------------------- --------------------- -------------------- -------------

^1^Coagulase-negative staphylococci. ^*2*^*Others included: Bacteroides fragilis, Candida albicans, Citrobacter, Diphteroids*spp.,*Enterobacter cloacae, Haemophilus influenzae* (type B), *Haemophilus parainfluenzae, Legionella pneumophila,*Leuconostoc*, Morganella morgani, Peptococcus*spp.,*Providncia stuartii, Serratia marsescens,*and*Stenotrophomonas maltophilia*.

^∗^p=\<0.05 considered significant.

###### 

Preresuscitation parameters.

  -------------------------- --------------------- --------------------- -------------
                             **Protocol N= 145**   **Control N= 145**    **p-value**
                                                                         
  **Continuous mean ± SD**                                                
                                                                         
  SBP (mmHg)                 104.7 ± 23.9          100.0 ± 26.0          0.114
                                                                         
  DBP (mmHg)                 59.2 ± 16.3           54.7 ± 16.0           0.019^∗^
                                                                         
  MAP (mmHg)                 73.7 ± 17.3           69.5 ± 17.6           0.043^∗^
                                                                         
  HR (bpm)                   106.2 ± 24.2          99.4 ± 25.3           0.021^∗^
                                                                         
  O~2~ Saturation (%)        92.8 ± 8.5            93.4 ± 7.1            0.533
                                                                         
  Temperature (°C)           37.7 ± 1.2            37.4 ± 1.4            0.071
                                                                         
  RR (breath/min)            23.9 ± 7.2            22.9 ± 6.4            0.196
                                                                         
  Glucose (mg/dl)            169.8 ± 102.9         172.3 ± 116.1         0.860
                                                                         
  WBC (x10^9^cells/L)        15,238.6 ± 11,683.5   16,412.4 ± 15,648.1   0.470
                                                                         
  Hemoglobin (g/dL)          11.0 ± 62.2           11.0 ± 2.3            0.935
                                                                         
  Hematocrit(%)              33.1 ± 6.9            33.1 ± 7.9            0.994
                                                                         
  Bicarbonate(mmol/L)        20.5 ± 6.0            19.9 ± 8.9            0.515
                                                                         
  BUN (mg/dL)                41.9 ± 29.9           55.9 ± 39.5           0.001^∗^
                                                                         
  Creatinine (mg/dL)         2.0 ± 1.4             2.8 ± 2.2             \<0.001^∗^
                                                                         
  Arterial pH                7.34 ± 0.1            7.34 ± 0.1            0.964
                                                                         
  INR                        1.8 ± 1.1             2.0 ± 1.3             0.397
                                                                         
  Lactate^1^ (mmol/L)        3.9 ± 2.5             3.8 ± 4.1             0.787
                                                                         
  Lactate \> 4 mmol/L        18 (12.4)             48 (33.1)             0.190
  -------------------------- --------------------- --------------------- -------------

^1^133 protocol patients had their lactate taken vs 67 controls.

^∗^p=\<0.05 considered significant.

###### 

Resuscitation parameters.

  ------------------------------------------------------------------- --------------------- -------------------- -------------
                                                                      **Protocol N= 145**   **Control N= 145**   **p-value**
                                                                                                                 
  ***Vital signs after 6 hours***                                                                                
                                                                                                                 
  **Continuous mean ± SD**                                                                                       
                                                                                                                 
  SBP (mmHg)                                                          103.3 ± 19.9          104.7 ± 18.9         0.595
                                                                                                                 
  DBP (mmHg)                                                          57.2 ± 13.0           59.1 ± 14.5          0.243
                                                                                                                 
  MAP (mmHg)                                                          69.8 ± 13.8           73.9 ± 14.9          0.022^∗^
                                                                                                                 
  HR (bpm)                                                            92.4 ± 21.0           91.9 ± 20.0          00.834
                                                                                                                 
  O2 Saturation (%)                                                   96.0 ± 11.2           97.1 ± 6.8           0.394
                                                                                                                 
  Temperature (°C)                                                    37.3 ± 0.9            37.4 ± 5.9           0.781
                                                                                                                 
  RR (breath/min)                                                     21.8 ± 5.5            21.0 ± 4.3           0.166
                                                                                                                 
  ***Resources variables***                                                                                      
                                                                                                                 
  **Continuous mean ± SD**                                                                                       
                                                                                                                 
  IV fluid requirements at first 6 hrs (L)                            3.8 ± 1.7             2.7 ± 2.0            \<0.001^∗^
                                                                                                                 
  IV fluid requirements at first 24 hrs (L)                           6.1 ± 2.1             4.9 ± 2.8            \<0.001^∗^
                                                                                                                 
  Time to initiation of antibiotics (hrs)                             2.0 ± 3.6             2.8 ± 2.6            0.054
                                                                                                                 
  Time to vasopressor/inotrope use within the 1st 24hrs (hrs)         9.1 ± 22.6            7.7 ± 7.0            0.67
                                                                                                                 
  Duration of vasopressor/inotrope treatment within 1st 24hrs (hrs)   50.9 ± 649.6          40.0 ± 56.1          0.234
                                                                                                                 
  **Categorical No (**%**)**                                                                                     
                                                                                                                 
  Vasopressor/inotrope use within 1st 24hrs                           88 (60.6)             52 (35.8)            \<0.001^∗^
                                                                                                                 
  CVC placement                                                       29 (21.2)             14 (9.9)             0.010^∗^
                                                                                                                 
  Mechanical ventilation                                              31 (21.5)             23 (15.9)            0.217
                                                                                                                 
  Steroid use                                                         50 (34.5)             54 (37.2)            0.624
                                                                                                                 
  Antibiotic use                                                      143 (98.6)            145 (100.0)          0.155
                                                                                                                 
  Appropriate antibiotic use^1^                                       91 (97.8)%            75 (91.5)            0.056
                                                                                                                 
  Antibiotics initiation in the ED                                    136 (93.8)            144 (99.3)           0.010^∗^
                                                                                                                 
  Antibiotics initiation in the ICU                                   4 (2.8)               1 (0.7)              0.176
                                                                                                                 
  Antibiotics initiation in the GPU                                   3 (2.1)               0 (0)                0.082
  ------------------------------------------------------------------- --------------------- -------------------- -------------

^1^Appropriate use of antibiotics was defined as preliminary antibiotic given in the first 48hrs of treatment covering the bacteria grown later in bacteriology.

###### 

Length of stay and mortality outcomes.

  -------------------------------- --------------------- -------------------- -------------
                                   **Protocol N= 145**   **Control N= 145**   **P-value**
                                                                              
  **Length of Stay (mean ± SD)**                                               
                                                                              
  ED (hours)                       26.0 ± 29.0           19.4 ± 28.8          0.051
                                                                              
  ICU (days)                       5.8 ± 6.9             12.0 ± 38.9          0.285
                                                                              
  GPU (days)                       7.02 ± 6.2            7.1 ± 3.8            0.913
                                                                              
  Hospital^1^ (days)               10.7 ± 8.7            15.3 ± 29.8          0.148
                                                                              
  **Mortality no.(**%**)**                                                     
                                                                              
  In-hospital                      46 (31.7)             69 (47.6)            0.006^∗^
                                                                              
  72-hour                          17 (11.7)             11 (7.6)             0.233
                                                                              
  28-day^2^                        30 (20.7)             47 (32.4)            0.014
  -------------------------------- --------------------- -------------------- -------------

^1^Hospital LOS days were calculated only for those that did not expire in hospital (as shorter LOS times may be associated with early deaths). ^2^28 patients (19.3%) and 14 (9.7%) of patients had unknown 28-day mortality in the protocol and control groups, respectively.

^∗^p=\<0.05 considered significant.

###### 

Multiple logistic regression for hospital mortality.

  ------------------------------------------ --------------------- -------------------- ------------------------------------------ -------------
                                             **Protocol N= 145**   **Control N= 145**                                               
                                                                                                                                   
                                                                                        **Adjusted OR** ^**2**^ **(CI 95**%**)**   **P-value**
                                                                                                                                   
  **Hospital mortality no.(**%**)**^**1**^   46 (31.7)             69 (47.6)            0.429 (0.213-0.864)                        0.018^∗^
  ------------------------------------------ --------------------- -------------------- ------------------------------------------ -------------

^1^Reference group is being the Control group.

^2^While controlling for the following: age, gender, diagnosis (severe sepsis or septic shock), systolic CHF: EF\<40%, DM, CAD, HTN, cerebrovascular accidents, CKD, CKD on HD, COPD emphysema, CVC placed, ET tube placed, MAP upon presentation to the ED, BUN, creatinine, and appropriate use of antibiotics.

^∗^p=\<0.05 considered significant.

[^1]: Academic Editor: Theodore J. Gaeta
